GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

Vaccines help your body learn to fight infections. Arexvy contains proteins from the RSV virus. These virus proteins will not make you sick or give you RSV. When these virus proteins come in ...

The Food and Drug Administration on Wednesday approved Arexvy, the world’s first vaccine for RSV, or respiratory syncytial virus — a scientific breakthrough 60 years in the making ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

The US Food and Drug Administration has approved a vaccine against the respiratory syncytial virus, or RSV, for adults 60 and older. This vaccine, called Arexvy, is made by the drug company GSK.

RSV season usually starts in the autumn and is worst in the winter. The vaccine, known as Arexvy, was approved for adults 60 and over, will likely be recommended by the CDC in June and available ...

or RSV -- and more are on the way. On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older.